The 2025 Endpoints 11 list spotlights eleven private biotech companies demonstrating cutting-edge innovation across diverse therapeutic areas, including AI-driven drug design, in vivo CAR-T therapies, autoimmune disease T-cell engagers, macrocycle biologics, and RNA-based platforms. Startups such as Chai Discovery, Umoja Biopharma, Candid Therapeutics, and Lila Sciences are highlighted for their ambitious programs and significant capital raised, collectively reshaping the biotech landscape and pushing frontiers in treatment modalities and drug discovery technologies.